drugset / Trial / NCT05883085
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies the effectiveness of anlotinib hydrochloride in the neoadjuvant therapy of locally advanced, or unresectable pheochromocytoma or paragangliom(PPGL). Anrotinib is used preoperatively in order to change unresectable tumors to resectable and reduce the high risk of surgery.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2023-12-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |